Nxera Pharma To Regain Full Rights To Gpr52 Agonist Program For Schizophrenia
18/12/2025 23:33
Dec 19 (Reuters) - Nxera Pharma Co Ltd 4565.T: NXERA PHARMA CO LTD: NXERA PHARMA TO REGAIN FULL RIGHTS TO GPR52 AGONIST PROGRAM FOR SCHIZOPHRENIA Source text: ID:nTSxr7f90e Further company coverage: 4565.T (Reporting by Tokyo Newsroom) ((+81345201189;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up